☆ 4.6 Letter

Letter concerning Objective response rate targets for recurrent glioblastoma clinical trials based on the historic association between ORR and median overall survival: Toward surrogate endpoints for phase II trials in patients with recurrent glioblastoma

NEURO-ONCOLOGY (2023)

Get Full Text
Add to Collection

Journal

NEURO-ONCOLOGY
Volume 25, Issue 8, Pages 1546-1547

Publisher

OXFORD UNIV PRESS INC
DOI: 10.1093/neuonc/noad071

Keywords

clinical trial; endpoint; glioblastoma; ORR; recurrent glioblastoma

Categories

Oncology Clinical Neurology

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available
Webinars Posters Questions Hubs Funding Journals Papers Connect Collections Reviewers About Us FAQs Mobile App Privacy Policy Terms of Use
© Peeref 2019-2024. All rights reserved.